Skip to content

The Efficacy of Adding Compound Amino Acids to the Treatment of Pediatric Bacterial Sepsis: A Multicenter, Double-Blind, Randomized Controlled Clinical Trial

The Efficacy of Adding Compound Amino Acids to the Treatment of Pediatric Bacterial Sepsis: A Multicenter, Double-Blind, Randomized Controlled Clinical Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500115558
Enrollment
Unknown
Registered
2025-12-29
Start date
2025-11-12
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bacterial sepsis

Interventions

control group:Normal saline combined with conventional treatment
Experimental group:Compound amino acids combined with conventional treatment.

Sponsors

The Third Affiliated Hospital Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1. Age: 1 to 18 years old, regardless of gender; 2. Diagnosed with "bacterial sepsis" at the above research institutions between June 2025 and December 2028, with the diagnostic criteria referring to the 2024 international consensus criteria for pediatric sepsis and septic shock: suspected bacterial infection + Phoenix Sepsis Score (PSS) >= 2 points; 3.All patients were enrolled after providing written informed consent, agreeing to the proposed hospitalization, and committing to adhere to the prescribed follow-up protocol.

Exclusion criteria

Exclusion criteria: 1.Those allergic to compound amino acid injection; 2.Comorbidities: viral/fungal infection, chronic renal failure, chronic hepatic failure, severe brain injury, severe malnutrition, metabolic diseases; 3.Disease severity: Cardiopulmonary arrest occurred within the past two hours, requiring cardiopulmonary resuscitation for more than 2 minutes, or death was considered imminent or inevitable during hospitalization; massive hemorrhage with hemorrhagic shock; 4.Those who disagree to participate in the clinical trial or cannot follow up regularly as planned; those who die due to voluntary discharge or withdrawal of treatment for personal reasons; 5.Have participated in another interventional clinical trial within the past 30 days.

Design outcomes

Primary

MeasureTime frame
The incidence of death or persistent organ dysfunction within 14 days of hospitalization;

Secondary

MeasureTime frame
The number of days with persistent fever in children patients;Number of days on invasive mechanical ventilation;Length of stay in PICU;White blood cell count (WBC), procalcitonin (PCT), C-reactive protein (CRP), inflammatory factors (such as IL-6, IL-10, TNF-a), and lactic acid level in the blood;Changes in Pediatric Sequential Organ Failure Assessment (pSOFA score);Number of days of vasoactive drug use;

Countries

China

Contacts

Public ContactChenZhuanggui

The Third Affiliated Hospital Sun Yat-sen University

chenzhuanggui@126.com+86 20 8525 3050

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026